Animals. Six-week-old SPF NC/NgaTndCrlj male mice were purchased from Charles River Japan (Osaka, Japan) and used at 7 weeks of age (body weight, 20-23 g) and 11-15 weeks (body weight, 24-27 g) for in vivo and in vitro study, respectively. Mice were given sterile distilled water and a commercial diet (CE-2; CLEA Japan Inc., Tokyo, Japan) ad libitum, and were housed in an animal facility that was maintained at 22-26°C with 40-69% humidity and a 12/12-hr light/dark cycle under conventional conditions. The procedures for all animal studies were approved by the Institutional Review Board of Japan's National Institute for Environmental Studies. Animals were treated humanely and with regard for alleviation of suffering.
Research
Phthalate esters, ubiquitously used as plasticizers in many polyvinyl chloride (PVC) products, have become widespread in the environment (Peijnenburg et al. 2008) . Diisononyl phthalate (DINP) is used in flooring, wire and cable, dip coating, coated fabrics, tubing, shoes, sealants, and artificial leather, and humans may be exposed to DINP by the oral, dermal, and inhalation routes (Kavlock et al. 2002) . It has been expected that general population exposure to DINP would not exceed levels of di-(2-ethylhexyl)phthalate (DEHP) (Kavlock et al. 2002) , which are estimated at 3-30 µg/kg body weight/day (Doull et al. 1999) . Plasticizers, including DINP, are not covalently bound to the plastics and can migrate into saliva and be swallowed (Earls et al. 2003; Kavlock et al. 2002) . Thus, children may be exposed to higher levels of DINP than are adults because infants and small children mouth toys and other articles containing DINP (Babich et al. 2004; Kavlock et al. 2002) .
Several epidemiologic studies have suggested that exposure to phthalate esters may be associated with develop ment of asthma, wheezing, and allergic symptoms (Bornehag et al. 2004; Jaakkola et al. 1999 Jaakkola et al. , 2004 Jaakkola et al. , 2006 . Bornehag et al. (2004) revealed the positive association between allergic asthma in children and phthalate esters in house dust. Thus, it is possible that phthalate esters in the environment may also be associated with development of the other allergic diseases such as atopic dermatitis (AD).
In our previous studies, DEHP enhanced AD-like skin lesions in atopic-prone NC/ Nga mice at hundreds-fold lower levels than the no observed adverse effect level (NOAEL) determined from histologic changes in the liver of rodents (Takano et al. 2006; Yanagisawa et al. 2008) . The enhancing effects of DEHP paralleled the infiltration of eosinophils, mast cell degranulation, and the expression of pro inflammatory proteins in inflamed skin. Furthermore, we have shown that DEHP enhanced differentiation of bonemarrow-derived dendritic cells (BMDCs) and promoted T-helper 2 (T H 2) cell response in spleno cytes from NC/Nga mice in vitro (Koike et al. 2009 ).
The chronic health effects of DINP, including organ toxicity, carcinogenicity, and reproductive toxicity, have been reviewed in dietary studies (Babich et al. 2004; Kavlock et al. 2002) . DINP, as a phthalate plasticizer with specific stereochemical and physicochemical characteristics, has also been shown to have an adjuvant effect on T H 2-dependent immuno globulin (Ig) production in mice (Larsen et al. 2002; Larsen and Nielsen 2008) . However, the effects of DINP on allergic diseases including AD have remained unclear.
In the present study, we investigated the effects of DINP on AD-like skin lesions in atopic-prone NC/Nga mice in vivo and on the immunologic responses of BMDCs and splenocytes in vitro. et al. 2006) . Twenty-four hours after the last injection of Dp (day 18), the animals were sacrificed, and histologic findings, protein levels of cytokines and chemokines in the ear tissue supernatants, and the levels of Ig and histamine in serum were evaluated.
Histologic evaluation. Right ears of mice were removed 24 hr after the last Dp injection (day 18) and were fixed in 10% neutral phosphate-buffered formalin (pH 7.2) and embedded in paraffin. Sections (3 µm) were routinely stained with hematoxylin and eosin (H&E) or with toluidine blue (pH 4.0). Histologic analy sis was performed using an AX80 microscope (Olympus, Tokyo, Japan). We measured the length of the cartilage and the numbers of infiltrated eosinophils and mast cells in each sample using a video micrometer (VM-30; Olympus). We also evaluated the degranulation of mast cells as non degranulated (0%), mildly degranulated (0-50%), or severely degranulated (> 50%), as described previously (Takano et al. 2006) .
Quantitation of cytokines/chemokines in the ear tissue. Right ears of mice were removed 24 hr after the last injection of Dp (day 18) and were homogenized and centrifuged as previously described (Takano et al. 1997) . Levels of interferon (IFN)-γ (Endogen, Cambridge, MA, USA), inter leukin (IL)-4 (Amersham, Buckinghamshire, UK), IL-5 (Endogen), IL-13 (R&D Systems, Minneapolis, MN, USA), eotaxin (R&D Systems), eotaxin-2 (R&D Systems), and thymic stromal lymphopoietin (TSLP; R&D Systems) in the ear tissue supernatants were measured by enzyme-linked immuno sorbent assay (ELISA) according to the manufacturers' instructions. The detection limits of IFN-γ, IL-4, IL-5, IL-13, eotaxin, and TSLP were less than 10, 5, 5, 1.5, 3, and 2.63 pg/mL, respectively. The detection limit of eotaxin-2 was not defined, and the assay range was 15.6-1,000 pg/mL. The total protein level in the ear tissue supernatants was measured by the Bradford method using a protein assay kit (Bio-Rad, Hercules, CA, USA). The values of cytokines/chemokines were compensated with the total protein and were expressed as picograms per milligram of total protein.
Quantitation of Ig and histamine in serum. Blood was sampled by cardiac puncture 24 hr after the last injection of Dp (day 18) and serum was collected. Levels of Dp-specific IgG 1 were measured by ELISA with solid-phase antigen, as previously described (Sadakane et al. 2002) . Levels of total IgE antibodies and histamine in serum were measured by OptELISA Set Mouse IgE (BD Biosciences, San Diego, CA, USA) and Histamine Enzyme Immunoassay Kit (SPI-BIO, Montigny le Bretonneux, France), respectively, according to the manufacturers' instructions.
Cell preparation for in vitro study. For the in vitro study, bone marrow cells and splenocytes were prepared as previously described (Koike et al. 2009 ). Briefly, the marrow was flushed with Dulbecco's calcium-and magnesium-free, phosphate-buffered saline (PBS; Takara Bio Inc., Shiga, Japan) and passed through nylon mesh; the red blood cells were then lysed with ammonium chloride. The spleen was pushed through a sterile stainless-steel wire mesh, and the red blood cells were similarly lysed. The cells were centrifuged at 400 × g for 5 min at 20°C. After washing with PBS, the cells were resuspended in culture medium R10, consisting of GIBCO RPMI 1640 medium (Invitrogen, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (MP Biomedicals Inc., Eschwege, Germany), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma, St. Louis, MO, USA), and 50 µM 2-mercapto ethanol (Invitrogen). The numbers of viable cells were determined by the trypan blue (Invitrogen) exclusion method.
Differentiation of BMDCs. Bone marrow cells (4 × 10 5 /mL) were cultured in R10 medium containing 20 ng/mL recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF; Sigma) at 37°C in a 5% CO 2 /95% air atmosphere. On day 3, the same volume of medium was added to the culture, and on day 6, half the medium was replaced with fresh medium. On day 8, nonadherent and loosely adherent cells were collected by gentle pipetting. The differentiated BMDCs were centrifuged at 400 × g for 5 min at 20°C and resuspended in fresh medium. The numbers of viable cells were determined by the trypan blue exclusion method.
Exposure of immune cells to DINP. DINP was dissolved in dimethyl sulfoxide (DMSO; Sigma) and diluted with R10. The DINP solution was sonicated for 3 min using an ultrasonic disrupter (UD-201; TOMY, Tokyo, Japan). In the presence of GM-CSF (10 ng/mL), BMDCs (1 × 10 6 /mL) were exposed to DINP (0, 0.1, 1, 10, or 100 µM) in R10 containing 0.1% DMSO for 24 hr. Thereafter, their chemokine production, phenotypes, and antigenpresenting activity were evaluated. Next, splenocytes (1 × 10 6 /mL) were exposed to DINP (0, 0.1, 1, 10, or 100 µM) in R10 containing 0.1% DMSO for 24 hr, and their cytokine production was examined. Moreover, splenocytes (1 × 10 6 /mL) were exposed to DINP (0, 0.001, 0.01, 0.1, 1, or 10 µM) in R10 containing 0.1% DMSO in the presence of Dp (10 µg/mL) for 72 hr. Thereafter, antigen-stimulated proliferation and cytokine production of the cells were measured. Each experiment was performed using three individual cultures obtained from three animals, and two or three independent experiments were repeated.
Fluorescence-activated cell-sorting (FACS) analysis. For FACS analysis of BMDCs, we used the following mono clonal antibodies: major histo compatibility complex (MHC) class II I-A/I-E (2G9, rat IgG 2a κ, fluorescein isothiocyanate conjugated; BD Biosciences, San Jose, CA, USA); co-stimulatory molecules CD80 [16-10A1, Ar Ham IgG 1 κ, phycoerythrin (PE) conjugated; BD Biosciences] and CD86 (GL1, rat IgG 2a κ, PE conjugated; BD Biosciences); and chemokine receptors CCR7 (4B12, rat IgG 2a κ, PE conjugated; Biolegend, San Diego, CA, USA) and CXCR4 (2B11/ CXCR4, rat IgG 2b κ, PE conjugated; BD Biosciences). After DINP exposure, the cells (3-5 × 10 5 ) were resuspended in 100 µL PBS with 0.3% bovine serum albumin and 0.05% sodium azide (Wako Pure Chemical Industries) and were incubated with 1 µg of each antibody for 30 min on ice. After incubation, the cells were washed, and the fluorescence was measured by a FACSCalibur (BD, Franklin Lakes, NJ, USA). For each sample, we collected fluorescence data from 10,000 cells and positive cells were expressed as percent of total events.
Antigen-presenting activity. We evaluated BMDC function by antigen-presenting activity and stimulating capacity for cytokine production from responder T cells as previously described (Koike et al. 2009 ). Briefly, DINPexposed BMDCs were treated with 50 µg/mL mitomycin C (Kyowa Hakko Kogyo, Tokyo, Japan) for 20 min at 37°C. Splenocytes were prepared from NC/Nga mice sensitized with 50 µg Dp and 1 mg aluminium hydroxide (three mice per experiment). T cells were isolated from the splenocytes using a nylon fiber column (Wako Pure Chemical Industries). Thereafter, Dp-sensitized T cells (2 × 10 5 ) and BMDCs (5 × 10 3 ) were cocultured in the presence of 2 µg Dp in 200 µL R10 medium in 96-well flat-bottom plates. The cocultures were performed in triplicate at 37°C in a 5% CO 2 /95% air atmosphere. After 91 hr, we measured T-cell proliferation as an indicator of antigen-presenting activity, and cytokine production from T cells.
Cell proliferation assay. We measured cell proliferation using a Cell-Proliferation ELISA kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. This technique is based on the incorporation of the pyrimidine analogue 5-bromo-2´-deoxyuridine (BrdU) instead of thymidine into the DNA of proliferating cells. Cell proliferation was measured by adding BrdU to each well 20 hr before the measurement.
Quantitation of cytokines/chemokines in the culture supernatants. The levels of thymus-and activation-regulated chemokine (TARC/CCL17; R&D Systems), macrophagederived chemokine (MDC/CCL22; R&D Systems), and IL-12p40 (Endogen) in the BMDC culture supernatants and the levels of IFN-γ (Endogen), 
Results
Effects of DINP on AD-like skin lesions. To evaluate whether DINP affects AD-like skin lesions induced by Dp, we examined ear thickening and observed macroscopic features. Intradermal injection of Dp significantly enhanced ear thickening compared with saline injection from 4 days after the first injection of Dp ( Figure 1A ; p < 0.05). IP injection with DINP significantly enhanced ear thickening compared with vehicle in the presence of intradermal Dp from 6 days after the first injection of Dp (p < 0.05). However, we observed no dose-dependent effects of DINP. The ear thickening was most prominent in animals treated with 15 mg/kg/day DINP in the presence of intradermal Dp (p < 0.05). This result paralleled the clinical scores, including dryness, wound severity, and edema (data not shown). We observed macroscopic features demonstrating that DINP aggravated AD-like skin lesions related to Dp (Figure 1B-D) .
Histologic changes in the skin. To evaluate whether DINP affects histologic changes in the skin related to Dp, we examined the skin specimens stained with H&E ( Figure 2A ,C,E) or toluidine blue ( Figure 2B,D,F) . We found no pathologic changes in the saline plus vehicle group (Figure 2A,B) . Intradermal injection of Dp induced the infiltration of eosinophils into the skin lesions compared with saline injection (Figure 2A ,C,G; p < 0.05). IP injection with 15 mg/kg/day DINP tended to aggravate the infiltration of eosinophils into the skin lesion compared with vehicle in the presence of intradermal Dp (Figure 2C ,E,G). In overall trend, these changes paralleled the severity of mast cell degranulation ( Figure 2B,D,F 
,H).
Protein expression of cytokines/chemokines in the skin. We investigated whether DINP affects the protein expression of T H 1/ T H 2 cytokines and chemokines in the skin related to Dp. Intradermal injection of Dp significantly increased the expression of IL-4, IL-5, and IL-13 and significantly decreased the expression of IFN-γ compared with saline injection [see Supplemental Material, Table 1 (doi:10.1289/ehp.0901255); IL-4, p < 0.01; IL-5, p < 0.05; IL-13, p < 0.01; IFN-γ, p < 0.01]. IP treatment with DINP did not clearly affect the expression of these cytokines, although DINP tended to decrease IFN-γ expression compared with vehicle in the presence of intradermal Dp. Dp injection alone increased the expression of eotaxin, eotaxin-2, and TSLP compared with saline injection (see Supplemental Material, Table 1 ; eotaxin, p < 0.01). However, DINP significantly decreased the expression of eotaxin and eotaxin-2 compared with vehicle in the presence of intradermal Dp (p < 0.05). On the other hand, DINP at 0.15 mg/kg/day significantly increased TSLP expression compared with vehicle in the presence of intradermal Dp (p < 0.05). The expression of IL-12p40 was not detected (data not shown).
Effects of DINP on the levels of Ig and histamine in serum. To evaluate the adjuvant capacity of DINP for Ig production, we measured the levels of Dp-specific IgG 1 and total IgE in serum. We also investigated whether DINP affects histamine release in serum related to Dp. Intradermal injection of Dp significantly increased the levels of Dp-specific IgG 1 and total IgE and tended to increase histamine levels in serum compared with saline injection [see Supplemental Material, Table 1 (doi:10.1289/ehp.0901255); p < 0.01]. IP DINP treatment did not affect the levels of Dp-specific IgG 1 and total IgE in serum. In the presence of intradermal Dp, DINP significantly increased histamine levels in serum compared with saline injection (p < 0.01), except at 1.5 mg/kg/day. However, we found no significant difference between DINP and vehicle in the presence of intra dermal Dp.
Effects of DINP on BMDCs in vitro. To evaluate whether DINP affects the phenotypes and function of BMDCs in NC/Nga mice, we examined the production of T H 1/ T H 2 cytokines and chemokines, the expression of cell surface molecules, and antigenpresenting activity of BMDCs after exposure to DINP in vitro. DINP exposure for 24 hr significantly increased the production of T H 2 chemokines, TARC/CCL17 ( Figure 3A ; 100 µM DINP, p < 0.05) and MDC/CCL22 ( Figure 3B ; 100 µM DINP, p < 0.05), from BMDCs compared with control (0 µM DINP). We did not detect the T H 1 cytokine IL-12p40 in any BMDC cultures (data not shown). DINP also significantly increased the *p < 0.05, and **p < 0.01 for Dp-treated groups compared with the saline + vehicle group. # p < 0.05 for Dp + DINP groups compared with the saline + vehicle group. § p < 0.05, and § § p < 0.01 for Dp + DINP 150 mg/kg/day versus Dp + vehicle. † p < 0.05, and † † p < 0.01 for Dp + DINP 15 mg/kg/day versus Dp + vehicle. ‡ p < 0.05 for Dp + DINP 1.5 mg/kg/day versus Dp + vehicle. ‡ ‡ p < 0.05 for Dp + DINP 0.15 mg/kg/day versus Dp + vehicle. Days after first sensitization 9 1 1 1 3 1 6 1 8
Saline + vehicle Dp + vehicle Dp + DINP 0.15 mg/kg/day Dp + DINP 1.5 mg/kg/day Dp + DINP 15 mg/kg/day Dp + DINP 150 mg/kg/day expression of the chemokine receptors CCR7 ( Figure 3C ; 100 µM DINP, p < 0.01) and CXCR4 ( Figure 3D ; 10 or 100 µM DINP, p < 0.05), MHC class II (Figure 3E ,F; 1 or 10 µM DINP, p < 0.01; 0.1 or 100 µM DINP, p < 0.05), CD80 ( Figure 3E ; 100 µM DINP, p < 0.05), and CD86 ( Figure 3F ; 1, 10, or 100 µM DINP, p < 0.01) on BMDCs compared with controls. After the increases, Dp-specific antigen-presenting activity of BMDCs was significantly enhanced by DINP compared with control ( Figure 4A ; 1 or 10 µM DINP, p < 0.01; 100 µM DINP, p < 0.05). The levels of IL-4 in the cocultures of T cells and BMDCs exposed to DINP were also increased compared with controls ( Figure 4B ; 1 µM DINP, p < 0.05; 10 µM DINP, p < 0.01). The levels of IFN-γ ( Figure 4C ) and IL-17 ( Figure 4D ) tended to increase in response to DINP exposure in the same manner as IL-4 without significance. The level of IL-10 was lower than the detection limit (data not shown).
Effects of DINP on splenocytes in vitro.
To evaluate whether DINP affects the activation of splenocytes in NC/Nga mice, we examined the production of T H 1/T H 2 cytokines and Dp-stimulated proliferation of splenocytes after exposure to DINP in vitro. DINP exposure for 24 hr significantly increased IL-4 production from splenocytes compared with controls ( Figure 5A ; 10 µM DINP, p < 0.05; 100 µM DINP, p < 0.01). The levels of IL-10, IFN-γ, and IL-12p40 were < 10 pg/mL, and we observed no effects of DINP (data not shown). On the other hand, 72-hr exposure to DINP in the presence of Dp significantly increased proliferation of splenocytes at 0.001-1 µM and decreased the proliferation at 10 µM compared with controls ( Figure 5B ; 0.001 or 1 µM DINP, p < 0.01; 0.01, 0.1, or 10 µM DINP, p < 0.05).
Discussion
In the present study, we found that DINP aggravated AD-like skin lesions related to Dp in NC/Nga mice. The aggravation was consistent with the degree of eosinophilic inflammation, mast cell degranulation, and TSLP expression in the inflamed ear. DINP also enhanced the expression of cell surface activation markers on BMDCs; the production of TARC/CCL17 and MDC/CCL22; and the Dp-specific antigen presentation, IL-4 production, and Dp-stimulated prolifera tion of splenocytes from NC/Nga mice in vitro.
DINP is ubiquitously used in PVC products and, along with DEHP, is widespread in the environment. Although previous studies have shown that DINP possesses adjuvant activity characterized by antigen-specific IgG 1 antibody production (Larsen et al. 2002; Larsen and Nielsen 2008) , the effects of DINP on allergic diseases or symptoms and on under lying cellular and molecular mechanisms remain unclear.
The present study showed that DINP (0.15, 1.5, 15, or 150 mg/kg/day) caused aggravation of AD-like skin lesions related to Dp in NC/Nga mice, as evidenced by macroscopic (Figure 1 ) and microscopic (Figure 2 ) examination. We observed no dose-dependent effects of DINP, and the symptoms were most prominent on exposure to 15 mg/kg/day DINP in the presence of intradermal Dp ( Figure 1A ). This dose of DINP has been reported as a NOAEL for general chronic oral toxicity in rats (Lington et al. 1997) . Additionally, based on oral toxicologic studies on DINP in rats, the NOAEL for developmental toxicity and reproductive toxicity is 100-200 and 665-802 mg/kg/day, respectively (Kavlock et al. 2002) . Accordingly, our present results indicate that DINP can aggravate AD-like skin lesions related to Dp at lower levels than those used in previous studies, whereas a NOAEL based on oral intake cannot be directly compared with an injected dose.
Compared with vehicle treatment, DINP exposure tended to increase hista mine release in serum [see Supplemental Material, Table 1 (doi:10.1289/ehp.0901255)] in the presence of intra dermal Dp. The increases in histamine may be one of the mechanisms underlying the aggravation of AD-like skin lesions by DINP. In contrast, DINP did not clearly affect Ig levels or the expression of T H 1/ T H 2 cytokines such as IFN-γ, IL-4, IL-5, and IL-13. However, DINP signifi cantly decreased eotaxin and eotaxin-2 expression in ear tissue in the presence of intradermal Dp, compared with vehicle (see Supplemental Material, Table 1 ), even though eosino philic inflammation and mast cell degradation in the ear were present in parallel with the aggravation of AD-like skin lesions (Figure 2 ). This result differed from that in our previous study on DEHP (Takano et al. 2006) , in which we observed increased expression of eotaxin and macrophage inflammatory protein-1α in the ear. It is possible that DINP induced the expression of T H 2 cytokines and chemokines at an earlier phase and that this induction might contribute to the aggravation of the symptoms. A time-course study is needed to elucidate the correlation between symptoms and inflammatory mediators. In addition, it is possible that DINP may aggravate AD-like skin lesions through mecha nisms different from those of DEHP. For instance, DINP enhanced TSLP expression compared with vehicle in the presence of intradermal Dp (see Supplemental Material, Table 1 ). Previous studies have shown that TSLP is associated with AD and asthma in humans (Soumelis et al. 2002; Ying et al. 2005 ) and mice (Li et al. 2005; Zhou et al. 2005) . TSLP is an epithelial-cell-derived IL-7-like cytokine that strongly activates dendritic cells. TSLP-activated dendritic cells produce T H 2-attracting chemokines (Soumelis et al. 2002) and then induce T H 2 cell activation, initiating allergic inflammation by triggering IgE production, eosinophilia, and mucus production (Liu 2006; Liu and Frederick 2009) . In a preliminary study, we observed that exposure to 0.15 mg/kg/day DINP further enhanced the expression of activation markers of antigenpresenting cells, including dendritic cells, and that these cell numbers in local lymph node cells compared with vehicle in the presence of intradermal Dp (data not shown). This result is consistent with the enhancement of TSLP expression. Therefore, DINP may activate dendritic cells in Dp-related inflammatory sites through the enhancement of TSLP production. The activated dendritic cells can migrate into local lymph nodes, leading to acceleration of antigen presentation and T H 2 cell activation.
Thus, we focused on dendritic cells and investigated the effects of DINP on BMDCs in vitro. In the present study we found that 24-hr DINP exposure significantly increased the production of the T H 2-attracting chemokines TARC/CCL17 ( Figure 3A ) and MDC/CCL22 ( Figure 3B) but not the T H 1-polarizing cytokine IL-12p40 (data not shown), and increased the expression of CCR7, CXCR4 ( Figure 3C,D) , MHC class II, CD80, and CD86 ( Figure 3E ,F) in BMDCs. CCR7 and CXCR4 are chemo kine receptors for regulating dendritic cell function and migration into draining lymph nodes (Kabashima et al. 2007) . MHC class II (Niederhuber and Shreffler 1977) and costimulatory molecules CD80 and CD86 (Freeman et al. 1993; Lenschow et al. 1993 ) are essential for antigen presentation. DINP exposure significantly enhanced Dp-specific antigen-presenting activity of BMDCs compared with the control ( Figure 4A ). DINP-exposed BMDCs consequently stimulated IL-4 production in the cocultures with Dp-sensitized T cells ( Figure 4B ). The production of IFN-γ and IL-17 in the co cultures was not significantly altered by DINP exposure (Figure 4C,D) . DINP also enhanced BMDC differentiation after 6-day culture of bone marrow cells in the presence of DINP (data not shown). However, DINP more clearly affected BMDC activation instead of BMDC differentiation. In contrast, our previous study (Koike et al. 2009) showed that DEHP may predominantly affect BMDC differentiation rather than BMDC activation. The different immune stimulatory effects of these phthalates may be related to their chemi cal structures and properties. Larsen and Nielsen (2008) suggested that the adjuvant effects of phthalates are highly influenced by both stereo chemical and physico chemical properties. Second, we investigated the effects of DINP on splenocytes in vitro in order to evaluate whether DINP affects systemic immune responses. Exposure to DINP for 24 hr significantly increased IL-4 production from splenocytes in a concentration-dependent manner ( Figure 5A ). The levels of IL-10, IFN-γ, and IL-12p40 were < 10 pg/mL, and we observed no effects of DINP (data not shown). In a previous study Lee et al. (2004) showed that in vitro and/or in vivo exposure to DEHP and DINP enhances IL-4 production in CD4 + T cells and activation of IL-4 gene promoter containing binding sites for the NFAT (nuclear factor of activated T cells) transcription factor. That study and our present findings suggest that DEHP and DINP may enhance allergic responses by enhancing IL-4 production in CD4 + T cells via an NFAT-dependent pathway. Further studies are needed to identify the signaling pathways, including transcriptional factors, associated with the effects of DEHP and DINP on T cells. Moreover, exposure to DINP at low concentrations (0.001-1 µM) for 72 hr significantly increased Dp-stimulated splenocyte proliferation ( Figure 5B ). The DINP-induced increase showed maximal activity at these concentrations and then decreased. We previously showed a similar effect with DEHP (Koike et al. 2009 ). Therefore, these results suggest that prolonged exposure of splenocytes to low concentrations of phthalates such as DEHP and DINP can activate their proliferation in the presence of antigen.
Conclusions
DINP can aggravate AD-like skin lesions related to Dp in NC/Nga mice at the same levels as the NOAEL for general toxicity. TSLP, in particular, may play a crucial role in this aggravation. Furthermore, DINP can enhance T H 2 responses through the activation of BMDCs and splenocytes in vitro. The mechanisms underlying the aggravation of AD-like skin lesions by DINP may be linked, in part, to the enhanced TSLP-mediated activation of dendritic cells and a direct or indirect activation of the immune cells. 
